P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971232.77003.b0 |
| _version_ | 1797280841344221184 |
|---|---|
| author | Stephen Opat Alessandra Tedeschi Bei Hu Kim Linton Pam Mckay Sophie Leitch Jie Jin Mingyuan Sun Magdalena Sobieraj-Teague Pier Luigi Zinzani Peter Browett Catherine Thieblemont Anna Marina Liberati Emmanuel Bachy Federica Cavallo Régis Costello Sunil Iyengar Roberto Marasca Heidi Mociková Jin Seok Kim Dipti Talaulikar Zhiyu Liang Jianfeng Xu Chris Tankersley Richard Delarue Melannie Co Judith Trotman |
| author_facet | Stephen Opat Alessandra Tedeschi Bei Hu Kim Linton Pam Mckay Sophie Leitch Jie Jin Mingyuan Sun Magdalena Sobieraj-Teague Pier Luigi Zinzani Peter Browett Catherine Thieblemont Anna Marina Liberati Emmanuel Bachy Federica Cavallo Régis Costello Sunil Iyengar Roberto Marasca Heidi Mociková Jin Seok Kim Dipti Talaulikar Zhiyu Liang Jianfeng Xu Chris Tankersley Richard Delarue Melannie Co Judith Trotman |
| author_sort | Stephen Opat |
| collection | DOAJ |
| first_indexed | 2024-03-07T16:46:04Z |
| format | Article |
| id | doaj.art-3c9661db98394abb8b543104f1e8aac8 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T16:46:04Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-3c9661db98394abb8b543104f1e8aac82024-03-03T06:25:14ZengWileyHemaSphere2572-92412023-08-017e77003b010.1097/01.HS9.0000971232.77003.b0202308003-00982P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIALStephen Opat0Alessandra Tedeschi1Bei Hu2Kim Linton3Pam Mckay4Sophie Leitch5Jie Jin6Mingyuan Sun7Magdalena Sobieraj-Teague8Pier Luigi Zinzani9Peter Browett10Catherine Thieblemont11Anna Marina Liberati12Emmanuel Bachy13Federica Cavallo14Régis Costello15Sunil Iyengar16Roberto Marasca17Heidi Mociková18Jin Seok Kim19Dipti Talaulikar20Zhiyu Liang21Jianfeng Xu22Chris Tankersley23Richard Delarue24Melannie Co25Judith Trotman261 Monash Health and Monash University, Clayton, Australia2 ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy3 Levine Cancer Institute/Atrium Health, Charlotte, United States4 Manchester Cancer Research Centre, Division of Cancer Sciences, Manchester, United Kingdom5 Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom6 North Shore Hospital, Auckland, New Zealand7 The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, China8 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China9 Flinders Medical Centre, Bedford Park, Australia10 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy11 Auckland City Hospital, Grafton, New Zealand12 APHP, Hôpital Saint-Louis, Hemato-oncology, Paris University Diderot, Paris, France13 Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni, Italy14 Lyon-Sud Hospital, University of Lyon, Hematology Department, Lyon, France15 University of Torino/AOU Città della Salute e della Scienza di Torino, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, Torino, Italy16 Conception University Hospital, Hematology and Cellular Therapy Department, Marseille, France17 Royal Marsden Hospital and Institute of Cancer Research, Sutton, United Kingdom18 University of Modena e Reggio Emilia, Modena, Italy19 University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Department of Clinical Hematology, Prague, Czech Republic20 Yonsei University College of Medicine, Division of Hematology, Department of Internal Medicine, Seoul, Korea, Rep. of South21 Australian National University, Canberra, Australia22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States22 BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Switzerland GmbH, Basel, Switzerland, and BeiGene USA, Inc., San Mateo, United States23 Concord Repatriation General Hospital, University of Sydney, Concord, Australiahttp://journals.lww.com/10.1097/01.HS9.0000971232.77003.b0 |
| spellingShingle | Stephen Opat Alessandra Tedeschi Bei Hu Kim Linton Pam Mckay Sophie Leitch Jie Jin Mingyuan Sun Magdalena Sobieraj-Teague Pier Luigi Zinzani Peter Browett Catherine Thieblemont Anna Marina Liberati Emmanuel Bachy Federica Cavallo Régis Costello Sunil Iyengar Roberto Marasca Heidi Mociková Jin Seok Kim Dipti Talaulikar Zhiyu Liang Jianfeng Xu Chris Tankersley Richard Delarue Melannie Co Judith Trotman P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL HemaSphere |
| title | P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL |
| title_full | P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL |
| title_fullStr | P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL |
| title_full_unstemmed | P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL |
| title_short | P1084: LONG-TERM EFFICACY AND SAFETY OF ZANUBRUTINIB (ZANU) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): FINAL ANALYSIS OF THE MAGNOLIA (BGB-3111-214) TRIAL |
| title_sort | p1084 long term efficacy and safety of zanubrutinib zanu in patients pts with relapsed refractory r r marginal zone lymphoma mzl final analysis of the magnolia bgb 3111 214 trial |
| url | http://journals.lww.com/10.1097/01.HS9.0000971232.77003.b0 |
| work_keys_str_mv | AT stephenopat p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT alessandratedeschi p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT beihu p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT kimlinton p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT pammckay p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT sophieleitch p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT jiejin p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT mingyuansun p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT magdalenasobierajteague p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT pierluigizinzani p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT peterbrowett p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT catherinethieblemont p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT annamarinaliberati p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT emmanuelbachy p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT federicacavallo p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT regiscostello p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT suniliyengar p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT robertomarasca p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT heidimocikova p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT jinseokkim p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT diptitalaulikar p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT zhiyuliang p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT jianfengxu p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT christankersley p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT richarddelarue p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT melannieco p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial AT judithtrotman p1084longtermefficacyandsafetyofzanubrutinibzanuinpatientsptswithrelapsedrefractoryrrmarginalzonelymphomamzlfinalanalysisofthemagnoliabgb3111214trial |